Sverre Heim - Genetic Mutations

Author Information

Sverre Heim is a distinguished researcher affiliated with the Section for Cancer Cytogenetics at the Institute for Cancer Genetics and Informatics, situated within The Norwegian Radium Hospital, Oslo University Hospital, in Oslo, Norway. His research primarily focuses on cancer genetics, with significant contributions to understanding chromosomal abnormalities and fusion genes in various cancers.

Research Contributions

Sverre Heim has made substantial contributions to the field of cancer cytogenetics, with a focus on the cytogenetic and molecular analyses of various tumors. His recent work includes studies on the fusion of genes in osteoclastic giant cell-rich tumors of bone, gastrointestinal stromal tumors, and pediatric rhabdomyosarcoma. He has also explored monosomy in mammary myofibroblastoma and therapy-induced chromosomal rearrangements leading to leukemia. His research is pivotal in elucidating the genetic mechanisms underlying tumor development and progression, highlighting the complexity of chromosomal rearrangements and their role as potential biomarkers.

Aliases

Sverre Heim is also known in the academic community by several aliases, including S Heim, S. Heim, and Sverre Heim. These variations are often used interchangeably in his publications.

Publication and Citation Metrics

Metric	Value
Total Citations	18,612
H-index	72
Total Publications	601

Publications:

Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone

DOI: 10.21873/cgp.20312

Year: 2022

Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity

DOI: 10.18632/oncotarget.28209

Year: 2022

Monosomy 13 in Mammary Myofibroblastoma

DOI: 10.21873/anticanres.15166

Year: 2021

Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.

DOI: 10.1200/JCO.2021.39.15_SUPPL.11535

Year: 2021

Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3

DOI: 10.21873/cgp.20242

Year: 2021

Several Fusion Genes Identified in a Spermatic Cord Leiomyoma With Rearrangements of Chromosome Arms 3p and 21q

DOI: 10.21873/cgp.20278

Year: 2021

Interstitial Deletions Generating Fusion Genes

DOI: 10.21873/cgp.20251

Year: 2021

Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a KAT6A-LEUTX Fusion Gene

DOI: 10.21873/anticanres.14940

Year: 2021

Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma

DOI: 10.21873/cgp.20293

Year: 2021

Rare KMT2A-ELL and Novel ZNF56-KMT2A Fusion Genes in Pediatric T-cell Acute Lymphoblastic Leukemia

DOI: 10.21873/cgp.20247

Year: 2021

How Do Genetic Mutations Affect Agriculture?

What is the Future of CFTR Gene Research?

How is Sickle Cell Trait Diagnosed?

What is Sanger Sequencing?

What is Meiosis?

What is the Role of Genetics in Cancer Treatment?

How is Data Collected in Populace Genomics?

What is the Mechanism of Action of TKIs?

What is Prenatal Screening?

What is the Future of Genetic Data Analysis?

Partnered Content Networks

Relevant Topics